Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230016/S004

MAGE-A4 IHC 1F9 pharmDx

Agilent Technologies, Inc. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONP230016/S004

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-21 for MAGE-A4 IHC 1F9 pharmDx, filed under P230016/S004 by Agilent Technologies, Inc. The supplement is a 30-Day Notice with the recorded reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The statement describes approval for a supplier's change to the manufacturing site for a device component.

This action concerns a supplier and manufacturing-site change for a component of an immunohistochemistry antibody assay (product code SBL, Pathology), not a new approval of the assay itself. The source does not identify the affected component, the supplier, the prior or new manufacturing site, or any performance data supporting the change. Whether the approved change alters device labeling or clinical use is not stated and remains unknown from this record.

FDA approval order statement

approval for a supplier's change to the manufacturing sight for a device component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 21, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230016/S004
Regulatory pathway
PMA supplement
Product code
SBL
Decision code
OK30
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.

Product code
SBL
FDA device class
3

For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230016 · Original PMA

    MAGE-A4 IHC 1F9 pharmDx

  2. P230016/S004 received

    Application receipt date recorded by FDA.

  3. P230016/S005 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  4. P230016/S003 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  5. P230016/S004 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230016

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalAug 1, 2024FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records